SIB-SCRT: The pelvic lymphatic drainage regions receive 25 Gy in 5 fractions (5 Gy per fraction). A ssequential boost to a total dose of 30 Gy in 6 fractions is delivered to the primary tumour and any radiologically suspicious lymph nodes.
CAPOX: * Oxaliplatin 130 mg/m² intravenously on day 1.
* Capecitabine 1,000 mg/m² orally twice daily on days 1-14.
Immunotherapy: \- Tislelizumab 200 mg intravenously on day 1.
Study summary
The biological effective dose of short-course radiotherapy is relatively lower compared to long-course radiotherapy, which may lead to an increased local recurrence rate in patients with mid to low rectal cancer who are at high risk of locally advanced disease due to insufficient radiation dose. Combining short-course radiotherapy with simultaneous integrated boost (SIB) and immunotherapy-chemo regimens could potentially further enhance tumor regression and improve local control, providing a promising treatment option for high-risk locally advanced rectal cancer patients. Therefore, this clinical trial aims to explore the safety and effectiveness of a short-course SIB radiotherapy regimen combined with immunotherapy and chemotherapy as neoadjuvant treatment for locally advanced rectal cancer, based on short-course radiotherapy combined with chemotherapy and immunotherapy.
Eligibility
Sex
ALL
Min age
18 Years
Max age
75 Years
Healthy volunteers
No
Inclusion Criteria:
* Participants must voluntarily agree to join this study and sign an informed consent form.
* Age at the time of signing the informed consent form must be between 18 and 75 years.
* Histologically confirmed diagnosis of rectal adenocarcinoma.
* High-risk locally advanced pMMR/MSS rectal cancer, categorized according to the AJCC/UICC 8th edition clinical staging and in reference to the inclusion criteria of the RAPIDO study, must meet at least one of the following conditions: cT4 stage, cN2 stage, involvement of the mesorectal fascia (MRF), or presence of laterally enlarged lymph nodes, with M0 status.
* The inferior margin of the tumor must be ≤10 cm from the anal verge.
* No prior anti-cancer treatment for rectal cancer (including local-regional and systemic therapy).
* Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) score of 0-1.
* At least one measurable lesion according to RECIST v1.1 criteria.
* Normal function of major organs without severe abnormalities in hematological, cardiovascular, pulmonary, hepatic, renal, or bone marrow function; laboratory tests must meet the following requirements:
Hemoglobin (Hb) ≥ 70 g/L; White blood cell count (WBC) ≥ 3.0 × 10\^9/L; Neutrophil count (NEUT) ≥ 1.5 × 10\^9/L; Platelet count (PLT) ≥ 100 × 10\^9/L; Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels ≤ 2.5 times the upper limit of normal (ULN); Total bilirubin (TBIL) ≤ 1.5 times the upper limit of normal (ULN); Renal function (serum creatinine, sCr) level ≤ 1.5 times the upper limit of normal (ULN).
Exclusion Criteria:
* Evidence of distant metastasis.
* Recurrent rectal cancer.
* Documented allergy to the investigational drug and/or its excipients.
* Contraindications to radiotherapy and/or chemotherapy.
* Women who are pregnant or breastfeeding.
* A history of other malignancies.
* Patients who have participated in other clinical trials involving investigational drugs within the last 6 months.
* Patients deemed inappropriate for inclusion in this study as determined by the investigator.
Primary outcome measure(s)
The Complete Response (CR) rate — 3 months The Complete Response (CR) rate refers to the sum of the pathological Complete Response (pCR) rate, defined as the absence of residual cancer cells in the surgical resection specimen observed microscopically, and the probability of patients achieving clinical Complete Response (cCR) who then undergo a watchful waiting (W\&W) approach. The primary endpoint of my study is the CR rate.
Trial sites (1)
Facility
City
Region
Status
Department of colorectal surgery, the Sixth Affiliated Hospital, Sun Yat-Sen University
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.